The final configurations of the gas molecules permeating GMs are given in Additional file 1: Figure S1.
Misonidazole, in oral dose of 1 gm-2, was given in conjunction with the first and last radiotherapy fractions, and dexamethasone, in a divided daily dose of 8 mg, was given throughout the radiation treatment, commencing after the first treatment.
If moderate or severe rejection was diagnosed, daily intravenous 1 gm methylprednisolone was given for 3 days.
When GM-CSF and trastuzumab were given on the same day, GM-CSF was given before trastuzumab infusion.
Assuming random mating and Hardy-Weinberg equilibrium (HWE), P gm, gf) is given in column 6 of Table II and P gc) can be calculated similarly as, A1 A2, andA1, and for genotypes gc = 11, 12, 21, 22, respectively.
The study intervention, GM-CSF, was given in a dose of 10 µg/kg subcutaneously daily for five consecutive days.
GM-CSF was given as half-hour intravenous infusions during two 10-day phases of daily treatments (separated by 10 days without GM-CSF) and over a final phase of 20 days of alternate day infusions.
Subcutaneous GM-CSF was given at 250 μg m 2 daily until the absolute neutrophil count was >10 000 mm–3, then was given every other day to maintain the absolute neutrophil count below 10 000 mm–3.
The median number of cycles given was 2 in arm A and 3 in arm B. 100%andd 89.4% of the planned dose of GM-CSF was given in arm A and arm B respectively.
GM-CSF was given alone to six patients during the first part of the study to determine a dose that would produce a peripheral leucocyte count (WCC) greater than or equal to 50 X 10 9) 1(-1) and was initially given at 3 micrograms kg-1 day-1 and escalated to 10 micrograms kg-1 day-1 after 10 days.
